Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3862100 | PMC |
| http://dx.doi.org/10.3747/pdi.2012.00098 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Evaluation of 99Tcm-DTPA orbit SPECT/CT combined with thyroid function test in the treatment of radioactive iodine I-131 in patients with thyroid-associated ophthalmopathy-hyperthyroidism.
J Med Biochem
November 2024
The Central Hospital of Xiaogan, Department of Nuclear Medicine, Xiaogan City, Hubei Province, China.
Background: Thyroid-associated ophthalmopathy (TAO) is an autoimmune response to inflammation of the thyroid and orbital tissue. This research evaluated the efficacy of 99Tcm-DTPA orbital SPECT/CT combined with thyroid function test in radioactive iodine I-131 (RAI) treatment of TAO-hyperthyroidism.
Methods: We retrospectively studied clinical activity score (CAS), blood thyrotropine (TSH), free triiodothyronine (FT3), free thyroxine (FT4), thickness of extra-ocular muscle (EOM), and uptake rate (UR) of 99Tcm-DTPA orbital SPECT/CT of 43 patients after 6 months of treatment with 20 mCi RAI.
Roxadustat-Induced Central Hypothyroidism Masked by Uremia at the Initiation of Hemodialysis: A Case Report.
Cureus
December 2024
Nephrology, Yokohama Municipal Citizen's Hospital, Yokohama, JPN.
Hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) is a novel class of orally administered medications for renal anemia in patients with end-stage renal disease (ESRD). Roxadustat, a HIF-PHI, has a structure similar to that of triiodothyronine and may work as an agonist for thyroid hormone receptor-beta in the pituitary gland and/or hypothalamus. Therefore, roxadustat may cause central hypothyroidism due to suppressing thyroid-stimulating hormone (TSH) release in the pituitary gland and/or thyrotropin-releasing hormone release in the hypothalamus.
View Article and Find Full Text PDFTHE SERUM CREATININE TO CYSTATIN RATIO IN THYROTOXICOSIS PATIENTS: A CASE-CONTROL STUDY.
Acta Endocrinol (Buchar)
January 2025
Zigong Fourth People's Hospital, Department of Endocrinology, Zigong, Sichuan, China.
Context: Previous studies have demonstrated a correlation between creatinine and cystatin levels and thyroid disorders.
Objective: To further investigate the diagnostic value of serum creatinine to cystatin C ratio in the diagnosis of thyrotoxicosis.
Design: One hundred eighty four thyrotoxicosis patients and 406 healthy controls were enrolled.
Treatment of Primary Hypothyroidism by Slow-Release Liothyronine Monotherapy.
Endocr Metab Immune Disord Drug Targets
January 2025
Endocrine Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Background: Combination therapy with levothyroxine (L-T4) and slow-release T3 (SRT3) in the treatment of hypothyroidism results in a normal triiodothyronine/thyroxine (T3/T4) ratio above that of L-T4 monotherapy. No clinical study has been reported with SRT3 monotherapy for hypothyroidism.
Methods: This study was conducted in two parts.
Background: Previous studies showed sex differences in the prevalences of both major depressive disorder (MDD) and subclinical hypothyroidism (SCH). This study aimed to further compare the prevalence and correlates of moderate-to-severe SCH between male and female Chinese MDD patients.
Methods: A total of 1706 first-episode drug naïve Chinese patients with MDD were recruited.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!